Literature DB >> 390211

Crescentic glomerulonephritis without immune deposits: clinicopathologic features.

M M Stilmant, W K Bolton, B C Sturgill, G W Schmitt, W G Couser.   

Abstract

Of 46 patients with acute crescentic glomerulonephritis involving 20 to 90% of glomeruli, 16 had no definable systemic disease and no significant glomerular immune deposits by immunofluorescent or electron microscopy. Anti-GBM antibody and circulating immune complexes were further excluded by radioimmunoassay and Raji cell assay in all patients tested. Clinical features included a 10:6 male:female ratio, mean age of 58 years (range, 13-77), disease duration of less than 3 months, rapidly deteriorating renal function, and frequent pulmonary manifestations. Nine patients had oliguria, serum creatinine concentrations over 6 mg/100 ml, and required dialysis, but three of these patients subsequently recovered renal function. These three patients and seven patients with creatinine concentrations of less than 6 mg/100 ml have not progressed to chronic renal failure. In this series, idiopathic acute crescentic glomerulonephritis without immune deposits was more common than was immune complex or anti-GBM nephritis. The clinical, laboratory, and pathologic characteristics of these patients were similar to those reported in anti-GBM and immune-complex-induced glomerulonephritis. These observations expand the spectrum of rapidly progressive crescentic glomerulonephritis. They suggest that glomerular immune deposits may be less important than other factors in determining the extent of renal injury and subsequent clinical course in crescentic glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 390211     DOI: 10.1038/ki.1979.24

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  26 in total

1.  Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis.

Authors:  R H Brons; M C de Jong; N K de Boer; C A Stegeman; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

2.  What sensitized cells just might be doing in glomerulonephritis.

Authors:  W Kline Bolton
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

3.  Pancreatitis and duodenitis from sarcoidosis: successful therapy with mycophenolate mofetil.

Authors:  Andrew S O'Connor; Farhad Navab; Michael J Germain; Jonathan K Freeman; Jeffrey G Mulhern; Michael H O'Shea; George S Lipkowitz; Robert L Madden; Gregory L Braden
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

4.  Immunoperoxidase autopsy study of crescentic glomerulonephritis with extracapillary proliferation.

Authors:  T Tóth
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

Review 5.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

6.  Autoantibodies to native myeloperoxidase in patients with pulmonary hemorrhage and acute renal failure.

Authors:  D E Roberts; C Peebles; J G Curd; E M Tan; R L Rubin
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

7.  Circulating and deposited immune complexes in patients with glomerular disease: immunopathologic correlations.

Authors:  I Stachura; T L Whiteside; R H Kelly
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

8.  Crescentic glomerulonephritis in CD4- and CD8-deficient mice. Requirement for CD4 but not CD8 cells.

Authors:  P G Tipping; X R Huang; M Qi; G Y Van; W W Tang
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

9.  What is myeloperoxidase doing in ANCA-associated glomerulonephritis?

Authors:  William G Couser; Richard J Johnson
Journal:  Kidney Int       Date:  2015-11       Impact factor: 10.612

Review 10.  [Rapidly progressive glomerulonephritis:classification, pathogenesis and clinical management].

Authors:  R Birck; F J Van Der Woude
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.